Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension

Bibliography

• SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. (1991) 325:293-302.
   PubMed Web of Science ®Google Scholar
• DUPREZ DA: Role of the rennin–angiotensin–aldosterone system in vascular remodelling and inflammation: a clinical review. J. Hypertens. (2006) 24:983-991
   Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2003) 39:E1-E8.
   Google Scholar
• AZIZI M, WEBB R, NUSSBERGER J, HOLLENBERG NK: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. (2006) 24:243-256.
   Google Scholar
• ALDERMAN MH, OOI WL, COHEN H, MADHAVAN S, SEALEY JE, LARAGH JH: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. (1997) 10:1-8.
   Web of Science ®Google Scholar
• ALDERMAN MH, MADHAVAN S, OOI WL, COHEN H, SEALEY JE, LARAGH JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. (1991) 324:1098-1104.
   PubMed Web of Science ®Google Scholar
• AZIZI M, MENARD J: Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation (2004) 109:2492-2499.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, BRADSTREET TE, McWILLIAMS EJ et al.: Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension (1995) 25:37-46.
   PubMed Web of Science ®Google Scholar
• TOWNSEND R, HAGGERT B, LISS C, EDELMAN JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin. Ther. (1995) 17:911-923.
   Google Scholar
• HELIN K, STOLL M, MEFFERT S, STROTH U, UNGER T: The role of angiotensin receptors in cardiovascular diseases. Ann. Med. (1997) 29:23-29.
   PubMed Web of Science ®Google Scholar
• WEBER MA, NEUTEL JM, ESSINGER I, GLASSMAN HN, BOGER RS, LUTHER RR: Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation (1990) 81:1768-1774.
   PubMed Web of Science ®Google Scholar
• NEUTEL JM, LUTHER RR, BOGER RS, WEBER MA: Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am. Heart J. (1991) 122:1094-1000.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, ADMIRAAL PJ, DERKX FH et al.: Comparison of blood pressure and angiotensin responses to the renin inhibitor RO42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J. Hypertens. (1993) 11:831-838.
   Google Scholar
• KOBRIN I, VISKOPER RJ, LASZT A, BOCK J, WEBER C, CHARLON V: Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am. J. Hypertens. (1993) 6:349-358.
   Web of Science ®Google Scholar
• FISHER ND, HOLLENBERG NK: Is there a future for renin inhibitors? Expert Opin. Invest. Drugs (2001) 10:417-426.
   Google Scholar
• RAHUEL J, RASETTI V, MAIBAUM J et al.: Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem. Biol. (2000) 7:493-504.
   PubMed Web of Science ®Google Scholar
• KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J: Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365:217-223.
   PubMed Web of Science ®Google Scholar
• WHO: World health report 2002; reducing risk, promoting healthy life. World Health Organization, Geneva, Switzerland (2002).
   Google Scholar
• REUTERS BUSINESS INSIGHTHEALTHCARE: The cardiovascular market outlook to 2008. Datamonitor PLC, London, UK (2003).
   Google Scholar
• BAUER JH, REAMS GP: The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch. Intern. Med. (1995) 155:1361-1368.
   PubMed Web of Science ®Google Scholar
• WEINEHALL L,OHGREN B, PERSSON M et al.: High remaining risk in poorly treated hypertension: the ‘rule of halves’ still exists. J. Hypertens. (2002) 20:2081-2088.
   Google Scholar
• DAHLÖF B, SEVER PS, POULTER NR et al. FOR THE ASCOT INVESTIGATORS: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet (2005) 366:895-906.
   PubMed Web of Science ®Google Scholar
• MAIBAUM J, FELDMAN D: Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin. Ther. Patents (2003) 13:589-603.
   Google Scholar
• STANTON A: Potential of renin inhibition in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. (2003) 4:6-10.
   Google Scholar
• KELLY DJ, WILKINSON-BERKA JL, GILBERT RE: Renin inhibition new potential for an old therapeutic target. Hypertension (2005) 46:471-472.
   PubMed Web of Science ®Google Scholar
• WOOD JM, MAIBAUM J, RAHUEL J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Comm. (2003) 308:698-705.
   Google Scholar
• RAHUEL J, RASETTI V, MAIBAUM J et al.: Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. (2000) 7:493-504.
   PubMed Web of Science ®Google Scholar
• WOOD JM, SCHNELL CR, CUMIN F, MENARD J, WEBB RL: Aliskiren, a novel orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens. (2005) 23:417-426.
   Google Scholar
• GANTEN D, WAGNER J, ZEH K et al.: Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl. Acad. Sci. USA (1992) 89:7806-7810.
   Google Scholar
• PILZ B, SHAGDARSUREN E, WELLNER M et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46:569-576.
   PubMed Web of Science ®Google Scholar
• WEBB RL, NAVARRETE AE, DAVIS S, DE GASPARO M: Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J. Hypertens. (1998) 16:843-852.
   Google Scholar
• GUYEN G, DELARUE F, BERROU J, RONDEAU E, SRAER JD: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. (1996) 50:1897-1903.
   PubMed Web of Science ®Google Scholar
• FISHER NDL, HOLLENBERG NK: Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. (2005) 16:592-599.
   Web of Science ®Google Scholar
• AZIZI M, MENARD J, BISSERY A, BURA-RIVIERE A, VAIDYANATHAN S, CAMISASCA RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II–renin feedback interruption. J. Am. Soc. Nephrol. (2004) 15:3126-3133.
   Web of Science ®Google Scholar
• AZIZI M, CHATELLIER G, GUYENE TT, MENARD J: Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation (1995) 92:825-834.
   PubMed Web of Science ®Google Scholar
• FISHER ND, ALLAN DR, GABOURY CL, HOLLENBERG NK: Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension (1995) 25:935-939.
   PubMed Web of Science ®Google Scholar
• AVIV A, HOLLENBERG NK, WEDER AB: Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. Kidney Int. (2004) 65:361-368.
   PubMed Web of Science ®Google Scholar
• STANTON A, JENSEN C, NUSSBERGER J, O’BRIEN E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42:1137-1143.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel, orally-effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Circulation (2005) 111:1012-1018.
   PubMed Web of Science ®Google Scholar
• O’BRIEN E, BARTON J, NUSSBERGER J et al.: Aliskiren provides antihypertensive efficacy and suppression of plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension (2006) (In Press).
   Google Scholar
• DIETERLE W, CORYNEN S, VAIDYANATHAN S, MANN J: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmacol. Ther. (2005) 43:527-535.
   Web of Science ®Google Scholar
• DIETERLE W, CORYNEN S, MANN J: Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol. (2004) 58:433-436.
   Web of Science ®Google Scholar
• DOLAN E, STANTON A, THIJS L et al.: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study. Hypertension (2005) 46:156-161.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK: Aldosterone in the development and progression of renal injury. Kidney Int. (2004) 66:1.
   PubMed Web of Science ®Google Scholar